Literature DB >> 32413286

A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.

Ka Yang1, Yu Zhao1, Xueqing Nie1, Hao Wu1, Bo Wang1, Chelsi M Almodovar-Rivera1, Haibo Xie2, Weiping Tang3.   

Abstract

Proteolysis-targeting chimeras (PROTACs) is a paradigm shift for small-molecule drug discovery. However, limited E3 ubiquitin ligase ligands with cellular activity are available. In vitro binding assays involve the expression and purification of a large amount of proteins and they often yield ligands that are inactive in cell-based assays due to poor cell permeability, stability, and other reasons. Herein, we report the development of a practical and efficient cell-based target engagement assay to evaluate the binding affinity of a small library of cereblon ligands to its E3 ligase in cells. Selected cell-permeable E3 ligase ligands derived from this assay are then used to construct HDAC6 degraders with cellular protein degradation activity. Because the assay does not involve any genetic engineering, it is relatively easy to transfer from one cell type to a different one.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CRBN; E3 ligase; HDAC6; IMiD; Lenalidomide; PROTAC; Pomalidomide; Thalidomide; target engagement; targeted protein degradation

Mesh:

Substances:

Year:  2020        PMID: 32413286      PMCID: PMC7368820          DOI: 10.1016/j.chembiol.2020.04.008

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  43 in total

1.  Impact of linker length on the activity of PROTACs.

Authors:  Kedra Cyrus; Marie Wehenkel; Eun-Young Choi; Hyeong-Jun Han; Hyosung Lee; Hollie Swanson; Kyung-Bo Kim
Journal:  Mol Biosyst       Date:  2010-10-04

2.  Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.

Authors:  Jiuling Yang; Yangbing Li; Angelo Aguilar; Zhaomin Liu; Chao-Yie Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2019-10-21       Impact factor: 7.446

Review 3.  Small-Molecule Target Engagement in Cells.

Authors:  Marc Schürmann; Petra Janning; Slava Ziegler; Herbert Waldmann
Journal:  Cell Chem Biol       Date:  2016-03-31       Impact factor: 8.116

4.  Intracellular insulin quantification by cell-ELISA.

Authors:  Parker Lyng Andersen; Patrick Vermette
Journal:  Exp Cell Res       Date:  2016-06-23       Impact factor: 3.905

5.  Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase.

Authors:  Sarah A Holstein; Jens Hillengass; Philip L McCarthy
Journal:  J Clin Oncol       Date:  2018-05-01       Impact factor: 44.544

6.  Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.

Authors:  Ka Yang; Yanling Song; Haibo Xie; Hao Wu; Yi-Ting Wu; Eric D Leisten; Weiping Tang
Journal:  Bioorg Med Chem Lett       Date:  2018-05-30       Impact factor: 2.823

7.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

8.  Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.

Authors:  Katherine A Donovan; Jian An; Radosław P Nowak; Jingting C Yuan; Emma C Fink; Bethany C Berry; Benjamin L Ebert; Eric S Fischer
Journal:  Elife       Date:  2018-08-01       Impact factor: 8.140

9.  Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.

Authors:  Blake E Smith; Stephen L Wang; Saul Jaime-Figueroa; Alicia Harbin; Jing Wang; Brian D Hamman; Craig M Crews
Journal:  Nat Commun       Date:  2019-01-10       Impact factor: 14.919

10.  Plasticity in binding confers selectivity in ligand-induced protein degradation.

Authors:  Radosław P Nowak; Stephen L DeAngelo; Dennis Buckley; Zhixiang He; Katherine A Donovan; Jian An; Nozhat Safaee; Mark P Jedrychowski; Charles M Ponthier; Mette Ishoey; Tinghu Zhang; Joseph D Mancias; Nathanael S Gray; James E Bradner; Eric S Fischer
Journal:  Nat Chem Biol       Date:  2018-06-11       Impact factor: 15.040

View more
  9 in total

Review 1.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 2.  Histone Deacetylases as Epigenetic Targets for Treating Parkinson's Disease.

Authors:  Yan Li; Zhicheng Gu; Shuxian Lin; Lei Chen; Valentina Dzreyan; Moez Eid; Svetlana Demyanenko; Bin He
Journal:  Brain Sci       Date:  2022-05-21

Review 3.  PROTACs: An Emerging Therapeutic Modality in Precision Medicine.

Authors:  Dhanusha A Nalawansha; Craig M Crews
Journal:  Cell Chem Biol       Date:  2020-08-13       Impact factor: 9.039

4.  Evaluation of the binding affinity of E3 ubiquitin ligase ligands by cellular target engagement and in-cell ELISA assay.

Authors:  Ka Yang; Yaxian Zhou; Brett L Roberts; Xueqing Nie; Weiping Tang
Journal:  STAR Protoc       Date:  2021-01-22

Review 5.  Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Authors:  Robert Jenke; Nina Reßing; Finn K Hansen; Achim Aigner; Thomas Büch
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

6.  Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins.

Authors:  Yaxian Zhou; Peng Teng; Nathan T Montgomery; Xiaolei Li; Weiping Tang
Journal:  ACS Cent Sci       Date:  2021-03-04       Impact factor: 14.553

Review 7.  Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders.

Authors:  Yoo Jin Jung; David Tweedie; Michael T Scerba; Dong Seok Kim; Maria Francesca Palmas; Augusta Pisanu; Anna R Carta; Nigel H Greig
Journal:  Front Neurosci       Date:  2021-03-29       Impact factor: 4.677

Review 8.  HDAC Inhibitors: Innovative Strategies for Their Design and Applications.

Authors:  Mateusz Daśko; Beatriz de Pascual-Teresa; Irene Ortín; Ana Ramos
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

Review 9.  Small-Molecule PROTACs for Cancer Immunotherapy.

Authors:  Zefan Liu; Yajun Zhang; Yucheng Xiang; Xin Kang
Journal:  Molecules       Date:  2022-08-25       Impact factor: 4.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.